Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON

By sjmartinez • May 8, 2025

Peters S, Oliner KS, L'Hernault A, Ratcliffe M, Madison H, Lai Z, Stewart R, Mann H, Lowery C, Garon EB, Mok T, Johnson ML. Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON. ESMO Open. 2025 May 6;10(5):105058. doi: 10.1016/j.esmoop.2025.105058. Epub ahead of print. PMID: 40334315.

Tags: durvalumab, Hematology/Oncology, non-small-cell lung cancer, POSEIDON, Publications, tremelimumab, tumor mutational burden

Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer

Silverstein J, Smick A, Johnson B, Konecny GE. Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Future Oncol. 2025[...]

DNA methylation patterns in breast cancer, paired benign tissue from ipsilateral and contralateral breast, and healthy controls

Dennis SR, Tsukioki T, Cottone G, Zhou W, Ganz PA, Sehl ME, Luo Y, Khan SA, Clare S. DNA methylation patterns in breast cancer, paired[...]

Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas

Harrington KJ, Champiat S, Brody JD, Cho BC, Romano E, Golan T, Hyngstrom JR, Strauss J, Oh DY, Popovtzer A, Gomez-Roca C, Perets R, Kim[...]